Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Assets (2022 - 2025)

Axsome Therapeutics (AXSM) has disclosed Assets for 4 consecutive years, with $689.8 million as the latest value for Q4 2025.

  • Quarterly Assets rose 21.34% to $689.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $689.8 million through Dec 2025, up 21.34% year-over-year, with the annual reading at $689.8 million for FY2025, 21.34% up from the prior year.
  • Assets hit $689.8 million in Q4 2025 for Axsome Therapeutics, up from $669.2 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $689.8 million in Q4 2025 to a low of $88.6 million in Q1 2022.
  • Historically, Assets has averaged $496.8 million across 4 years, with a median of $565.0 million in 2024.
  • Biggest five-year swings in Assets: skyrocketed 339.45% in 2023 and later fell 10.37% in 2024.
  • Year by year, Assets stood at $331.5 million in 2022, then skyrocketed by 77.46% to $588.2 million in 2023, then fell by 3.36% to $568.5 million in 2024, then increased by 21.34% to $689.8 million in 2025.
  • Business Quant data shows Assets for AXSM at $689.8 million in Q4 2025, $669.2 million in Q3 2025, and $639.8 million in Q2 2025.